health 🔬 Moderna-Merck cancer vaccine shows promise in melanoma trial
A personalized mRNA cancer therapy by Moderna and Merck showed positive results in a Phase 3 trial for melanoma. The trial involved 1,137 patients with resected, high-risk melanoma, announced on August 19, 2026. The combination therapy met the primary endpoint of recurrence-free survival and a key secondary endpoint. This approach aims to teach the immune system to destroy specific cancer cells using individualized targets. Further detailed findings are expected to be presented at a future medical meeting. 🔬